Integra LifeSciences Holdings reported second-quarter 2026 sales of US$418.76 million and net income of US$4.48 million, swinging from a large prior-year net loss to a modest profit. The company issued third-quarter revenue guidance of US$410 million to US$425 million and slightly trimmed its full-year 2026 revenue outlook to a range of US$1.65 billion to US$1.70 billion, citing foreign exchange headwinds. The return to profitability signals operational progress, while the guidance trim reflects currency translation rather than weakening underlying demand.
Integra LifeSciences HoldingsFX headwinds trim 2026 outlook, but profitability improves